We are live on
!
Find out more
UOC
UBS O'Connor Portfolio holdings
AUM
$3.76B
1-Year Est. Return
62.41%
This Fund
S&P 500
This Quarter
Est. Return
+0.05%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$3.55B
AUM Growth
+$59.4M
(+1.7%)
Cap. Flow
-$31.8M
Cap. Flow
% of AUM
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
49.57%
Holding
665
New
156
Increased
155
Reduced
111
Closed
128
Avg Time Held Equity + Options
3.9
quarters
Top 10 Avg Time Held Equity + Options
0.8
quarters
Top 20 Avg Time Held Equity + Options
1.2
quarters
Avg Time Held Equity only
4.3
quarters
Top 10 Avg Time Held Equity only
0.8
quarters
Top 20 Avg Time Held Equity only
1.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HashiCorp, Inc. Class A Common Stock
HCP
|
+$138M |
| 2 |
Equitrans Midstream Corporation Common Stock
ETRN
|
+$131M |
| 3 |
Endeavor Group Holdings, Inc.
EDR
|
+$127M |
| 4 |
Marathon Oil Corporation
MRO
|
+$123M |
| 5 |
ChampionX
CHX
|
+$98.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pioneer Natural Resource Co.
PXD
|
+$638M |
| 2 |
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$51.2M |
| 3 |
Discover Financial Services
DFS
|
+$45.1M |
| 4 |
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
|
+$18.4M |
| 5 |
Norfolk Southern
NSC
|
+$17.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 26.53% |
| 2 | Technology | 21.03% |
| 3 | Healthcare | 14.68% |
| 4 | Industrials | 8.19% |
| 5 | Miscellaneous | 6.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
501
CALL
GSK
GSK
$93.2B
| $7K | ﹤0.01% |
+70,000
| New | +$2.94M |
2024 Q2
0 quarters
|
|
502
PUT
Hilton Worldwide
HLT
$73.5B
| $6.59K | ﹤0.01% |
15,500
| – | – |
2022 Q1
9 quarters
|
|
503
PUT
Western Digital
WDC
$149B
| $6.31K | ﹤0.01% |
19,184
| – | – |
2023 Q1
5 quarters
|
|
504
Brand Engagement Network Warrant
BNAIW
$888K
| $5.91K | ﹤0.01% |
153,567
| – | – |
2024 Q1
1 quarter
|
|
505
PUT
Sarepta Therapeutics
SRPT
$1.89B
| $5.63K | ﹤0.01% |
+15,000
| New | +$1.93M |
2024 Q2
0 quarters
|
|
506
MultiSensor AI Holdings Warrant
MSAIW
$920K
| $5.01K | ﹤0.01% |
145,732
| – | – |
2023 Q4
2 quarters
|
|
|
VRNA
507
CALL
DELISTED
Verona Pharma
VRNA
| $5K | ﹤0.01% |
+40,000
| New | +$584K |
2024 Q2
0 quarters
|
|
508
CALL
X4 Pharmaceuticals
XFOR
$289M
| $5K | ﹤0.01% |
+6,667
| New | +$218K |
2024 Q2
0 quarters
|
|
509
Borealis Foods Inc Warrant
BRLSW
$750K
| $4.92K | ﹤0.01% |
72,293
| – | – |
2024 Q1
1 quarter
|
|
510
Syntec Optics Holdings Warrant
OPTXW
$27.4M
| $4.38K | ﹤0.01% |
33,069
| – | – |
2022 Q1
9 quarters
|
|
511
CALL
BridgeBio Pharma
BBIO
$12.8B
| $4.38K | ﹤0.01% |
+35,000
| New | +$957K |
2024 Q2
0 quarters
|
|
512
CALL
CRISPR Therapeutics
CRSP
$5.16B
| $4.38K | ﹤0.01% |
25,000
+9,000
| +56% | +$521K |
2023 Q4
2 quarters
|
|
513
DELISTED
Corner Growth Acquisition Corp. 2 Warrants
TRONW
| $3.97K | ﹤0.01% |
116,665
| – | – |
2021 Q3
11 quarters
|
|
514
Royalty Management Holding Warrant
RMCOW
| $3.85K | ﹤0.01% |
+226,579
| New | +$6K |
2024 Q2
0 quarters
|
|
515
CALL
Merck
MRK
$359B
| $3.8K | ﹤0.01% |
+20,000
| New | +$2.58M |
2024 Q2
0 quarters
|
|
516
CALL
Intellia Therapeutics
NTLA
$1.83B
| $3.75K | ﹤0.01% |
30,000
+5,000
| +20% | +$119K |
2024 Q1
1 quarter
|
|
517
Tevogen Inc Warrant
TVGNW
$1.25M
| $3.75K | ﹤0.01% |
185,416
| – | – |
2022 Q1
9 quarters
|
|
518
CALL
DELISTED
Revance Therapeutics, Inc.
RVNC
| $3K | ﹤0.01% |
+120,000
| New | +$410K |
2024 Q2
0 quarters
|
|
519
Roadzen Inc Warrants
RDZNW
| $2.69K | ﹤0.01% |
67,181
| – | – |
2022 Q2
8 quarters
|
|
520
DELISTED
Finnovate Acquisition Corp. Warrants
FNVTW
| $2.63K | ﹤0.01% |
130,406
| – | – |
2021 Q4
10 quarters
|
|
521
PUT
Hyatt Hotels
H
$15.3B
| $2K | ﹤0.01% |
16,000
| – | – |
2022 Q1
9 quarters
|
|
522
CALL
Alphatec Holdings
ATEC
$1.65B
| $1K | ﹤0.01% |
+40,000
| New | +$466K |
2024 Q2
0 quarters
|
|
523
DELISTED
BlueRiver Acquisition Corp. Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50
BLUA.WS
| $748 | ﹤0.01% |
49,521
| – | – |
2022 Q1
9 quarters
|
|
524
DELISTED
SEP Acquisition Corp Warrants
SEPAW
| $663 | ﹤0.01% |
80,900
| – | – |
2022 Q4
6 quarters
|
|
525
DELISTED
WinVest Acquisition Corp. Warrant
WINVW
| $270 | ﹤0.01% |
18,392
| – | – |
2023 Q1
5 quarters
|
|
Similar funds
FNBT
ACI
RC
A
CGL
CB
JCM
MPM
UBS O'Connor's Q2 2024 Portfolio in Review
As of Q2 2024, UBS O'Connor held 665 positions worth $3.55B, up 1.7% from $3.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
UBS O'Connor's Q2 2024 filing shows 156 new, 155 increased, 111 reduced and 128 closed positions. Its largest new stake was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M. The largest sale was Pioneer Natural Resource Co., an estimated $638M.
By sector, the portfolio is most concentrated in Energy at 27% of assets, down from 34% a quarter earlier, followed by Technology and Healthcare.
- UBS O'Connor's largest Q2 2024 buy was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M.
- UBS O'Connor added most to HashiCorp, Inc. Class A Common Stock in Q2 2024, an estimated $138M increase.
- UBS O'Connor's biggest Q2 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $51.2M.
- UBS O'Connor fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $638M.
- UBS O'Connor's ten largest holdings make up 50% of its $3.55B portfolio in Q2 2024.
- UBS O'Connor opened 156 new positions and closed 128 in Q2 2024.
- UBS O'Connor's portfolio value rose 1.7% quarter-over-quarter to $3.55B.
Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.